PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?

PTC Therapeutics (PTCT) shares ended the last trading session 7.2% higher at $78.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.2% gain over the past four weeks.Last month, the company reported robust financial results for the first quarter of 2026. The growing investor confidence related to PTC Therapeutics’ marketed product Sephience (sepiapterin), which is approved for the treatment of phenylketonuria (PKU) and continues to see a strong launch, might have driven the recent share price rally.This biopharmaceutical company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +113.3%. Revenues are expected to be $297.27 million, up 66.2% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For PTC Therapeutics, the consensus EPS estimate for the quarter has been revised 156% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on PTCT going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>PTC Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, BioNTech SE Sponsored ADR (BNTX), closed the last trading session 3% higher at $92.22. Over the past month, BNTX has returned 2%.BioNTech's consensus EPS estimate for the upcoming report has changed +0.3% over the past month to -$2.44. Compared to the company's year-ago EPS, this represents a change of -34.1%. BioNTech currently boasts a Zacks Rank of #3 (Hold).Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks